Home Newsfeeds Oppenheimer Maintains Outperform on Etsy, Raises Price Target to $150

Oppenheimer Maintains Outperform on Etsy, Raises Price Target to $150

Oppenheimer analyst Jason Helfstein maintains Etsy (NASDAQ:ETSY) with a Outperform and raises the price target from $125 to $150.

byBenzinga Newsdesk

January 27, 2023

1 minute read

Oppenheimer analyst Jason Helfstein maintains Etsy (NASDAQ:ETSY) with a Outperform and raises the price target from $125 to $150.

Media
News

What’s Going On With Exxon Mobil Stock Tuesday?

By Anusuya Lahiri

February 13, 2:32 PM

Exxon Mobil Corp (XOM) faces accusations from climate activist investors for using bullying tactics and undermining shareholders' rights.

XOM

Cowen & Co. Maintains Outperform on Biogen, Lowers Price Target to $270

By Benzinga Newsdesk

July 21, 10:22 AM

Cowen & Co. analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $285 to $270.

BIIB

David Kanen, President Of KWM LLC Issues Letter To The Egain Board Calling For The Formation Of A Special Committee And Sale Of Egan. He Also Excoriates CEO Ashu Roy

By Benzinga Newsdesk

December 4, 9:12 AM

Dear EGAN Board of Directors,We, Kanen Wealth Management, LLC, owner of approximately 7% of eGain Corporation's ("EGAN" or the "Company") common shares, are calling on the board to formally hire an investment banker and

EGAN

Soleno Therapeutics Announces Peer-Reviewed Publication Of Data Comparing DCCR Treatment To The Natural History Of Prader-Willi Syndrome

By Benzinga Newsdesk

April 30, 8:15 AM

Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the publication of the comparison of results

SLNO

Oppenheimer Maintains Outperform on Etsy, Raises Price Target to $150

Related Posts

What’s Going On With Exxon Mobil Stock Tuesday?

Cowen & Co. Maintains Outperform on Biogen, Lowers Price Target to $270

David Kanen, President Of KWM LLC Issues Letter To The Egain Board Calling For The Formation Of A Special Committee And Sale Of Egan. He Also Excoriates CEO Ashu Roy

Soleno Therapeutics Announces Peer-Reviewed Publication Of Data Comparing DCCR Treatment To The Natural History Of Prader-Willi Syndrome